Patents by Inventor Ligang Qian
Ligang Qian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11553713Abstract: Disclosed are compositions and methods of pest control. The composition contains one or more active agents such as a polyalcohol, carbohydrate, nucleobase or nucleotide compound or derivative and one or more inactive ingredients which function as attractants or nutrients. The combination of the active agent(s) and the inactive ingredients achieves synergistic effect in pest control.Type: GrantFiled: September 21, 2016Date of Patent: January 17, 2023Inventors: Chunbo Zhang, Ligang Qian, Hongyue Zhang
-
Publication number: 20220380310Abstract: A compound has Formula I: R1 is hydrogen, hydroxy, halogen, nitro, amino, alkyl, alkoxy, alkylamino, cycloalkyl, cycloalkyamino, heterocyclyl, aryl, heteroaryl, —NR7R8, —CO—R10, or —NH—CO—R10; L is a bond, a heterocyclic bivalent group, a heteroaromatic bivalent group, or an aromatic bivalent group; M is a bond, alkyl, aryl, heterocyclic bivalent group, heteroaromatic bivalent group, or aromatic bivalent group; X is a bond, —O—, —S—, —SO2—, —CO—, —NR9—, —(CH2)m—, or heterocyclic bivalent group, m is 1, 2, 3, 4, 5, or 6; Y is a bond, —NH—, heterocyclic bivalent group, heteroaromatic bivalent group, bivalent benzyl group, or aromatic bivalent group; and Z is hydrogen, halogen, alkyl, aryl, heterocyclyl, heteroaryl, —NR7R8, —CO—R10, or —NH—CO—R10; R7, R8, and R9 are independently hydrogen, hydroxy, halogen, nitro, amino, alkyl, alkoxy, alkylamino, cycloalkyl, cycloalkyamino, heterocyclyl, or heteroaryl; and R10 is —O-tert-butyl, —CH2CH2-phenyl, hydrogen, hydroxy, halogen, nitro, amino, alkyl, alkoxy, alkylamType: ApplicationFiled: June 29, 2020Publication date: December 1, 2022Inventors: Ligang QIAN, Chunbo ZHANG
-
Publication number: 20200236932Abstract: Disclosed are compositions and methods of pest control. The composition contains one or more active agents such as a polyalcohol, carbohydrate, nucleobase or nucleotide compound or derivative and one or more inactive ingredients which function as attractants or nutrients. The combination of the active agent(s) and the inactive ingredients achieves synergistic effect in pest control.Type: ApplicationFiled: September 21, 2016Publication date: July 30, 2020Inventors: Chunbo Zhang, Ligang Qian, Hongyue Zhang
-
Patent number: 7820814Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.Type: GrantFiled: March 6, 2009Date of Patent: October 26, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Rajeev S. Bhide, Zhen-Wei Cai, Ligang Qian, Stephanie Barbosa, Louis Lombardo, Jeffrey Robl
-
Publication number: 20090170853Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.Type: ApplicationFiled: March 6, 2009Publication date: July 2, 2009Inventors: Rajeev S. Bhide, Zhen-Wei Cai, Ligang Qian, Stephanie Barbosa, Louis Lombardo, Jeffrey Robl
-
Patent number: 7547711Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.Type: GrantFiled: February 8, 2006Date of Patent: June 16, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Robert M. Borzilleri, Rajeev S. Bhide, John S. Tokarski, Peter Zheng, Ligang Qian, Zhen-Wei Cai
-
Patent number: 7521450Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.Type: GrantFiled: August 2, 2007Date of Patent: April 21, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Rajeev S. Bhide, Zhen-Wei Cai, Ligang Qian, Stephanie Barbosa, Louis Lombardo, Jeffrey Robl
-
Publication number: 20070299075Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.Type: ApplicationFiled: August 2, 2007Publication date: December 27, 2007Inventors: Rajeev Bhide, Zhen-Wei Cai, Ligang Qian, Stephanie Barbosa, Louis Lombardo, Jeffrey Robl
-
Patent number: 7265113Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.Type: GrantFiled: January 13, 2005Date of Patent: September 4, 2007Assignee: Bristol-Myers Squibb CompanyInventors: Rajeev S. Bhide, Zhen-Wei Cai, Ligang Qian, Stephanie Barbosa, Louis Lombardo, Jeffrey Robl
-
Patent number: 7244733Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.Type: GrantFiled: February 2, 2006Date of Patent: July 17, 2007Assignee: Bristol-Myers Squibb CompanyInventors: John T. Hunt, Rajeev S. Bhide, Robert Michael Borzilleri, Ligang Qian
-
Patent number: 7112675Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.Type: GrantFiled: July 27, 2005Date of Patent: September 26, 2006Assignee: Bristol-Myers Squibb CompanyInventors: John T. Hunt, Rajeev S. Bhide, Robert Michael Borzilleri, Ligang Qian
-
Patent number: 7102002Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.Type: GrantFiled: June 14, 2005Date of Patent: September 5, 2006Assignee: Bristol-Myers Squibb CompanyInventors: Zhen-wei Cai, Louis J. Lombardo, Rajeev S. Bhide, Ligang Qian, Donna D. Wei, Stephanie Barbosa
-
Patent number: 7084160Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.Type: GrantFiled: June 18, 2003Date of Patent: August 1, 2006Assignee: Bristol-Myers Squibb CompanyInventors: Robert M. Borzilleri, Rajeev S. Bhide, John S. Tokarski, Peter Zheng, Ligang Qian, Zhen-Wei Cai
-
Publication number: 20060135576Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.Type: ApplicationFiled: February 8, 2006Publication date: June 22, 2006Inventors: Robert Borzilleri, Rajeev Bhide, John Tokarski, Peter Zheng, Ligang Qian, Zhen-Wei Cai
-
Publication number: 20060128709Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.Type: ApplicationFiled: February 2, 2006Publication date: June 15, 2006Inventors: John Hunt, Rajeev Bhide, Robert Borzilleri, Ligang Qian
-
Publication number: 20060009454Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.Type: ApplicationFiled: June 14, 2005Publication date: January 12, 2006Inventors: Zhen-wei Cai, Louis Lombardo, Rajeev Bhide, Ligang Qian, Donna Wei, Stephanie Barbosa
-
Publication number: 20060004007Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.Type: ApplicationFiled: July 27, 2005Publication date: January 5, 2006Inventors: John Hunt, Rajeev Bhide, Robert Borzilleri, Ligang Qian
-
Patent number: 6982265Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.Type: GrantFiled: May 18, 2000Date of Patent: January 3, 2006Assignee: Bristol Myers Squibb CompanyInventors: John T. Hunt, Rajeev S. Bhide, Robert Michael Borzilleri, Ligang Qian
-
Patent number: 6933386Abstract: The present invention relates to a process for preparing certain pyrrolotriazine compounds of the formula and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.Type: GrantFiled: July 18, 2003Date of Patent: August 23, 2005Assignee: Bristol Myers Squibb CompanyInventors: Rajeev S. Bhide, Junying Fan, Luca Parlanti, Stephanie Barbosa, Ligang Qian, Zhen-Wei Cai, Francis S. Gibson
-
Publication number: 20050124621Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.Type: ApplicationFiled: January 13, 2005Publication date: June 9, 2005Inventors: Rajeev Bhide, Zhen-Wei Cai, Ligang Qian, Stephanie Barbosa, Louis Lombardo, Jeffrey Robl